Skip to main content

Table 3 Association between baseline factors and significant response to rGH at 1-year follow-up in 44 patients

From: Recombinant growth hormone therapy in children with short stature in Kuwait: a cross-sectional study of use and treatment outcomes

Baseline factors at rGH initiation

Odds Ratio [95 % CI]

P value

Male Gender

0.24 [0.04–1.49]

0.127

Age at initiation

0.56 [0.36–0.87]

0.011

Pre-pubertal at initiation of therapy

0.06 [0.001–1.98]

0.114

Height SDS at initiation

2.61 [0.41–16.80]

0.310

BMI SDS at initiation

0.49 [0.22–1.12]

0.092

  1. rGH Recombinant Growth Hormone, SDS Standard Deviation Score, BMI Body Mass Index; *Height SDS change ≥0.3.
Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us